GlobeNewswire by notified

Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate

Share

AGC Biologics is producing vaccine materials for early-stage trials at its Heidelberg facilities

Seattle, March 31, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The CDMO has manufactured phase I clinical trial materials for Allergy Therapeutics’ novel virus-like particle (VLP)-based peanut allergy vaccine candidate (“VLP Peanut”), ahead of trial commencement later this year.

Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply. The United States Food & Drug Administration (FDA) recently cleared Allergy Therapeutics Investigational New Drug application (IND), which included data generated in this collaborative effort and granted the VLP Peanut vaccine candidate a clear path to a Phase I product trial in the U.S.

“Allergy Therapeutics is creating a strong vaccine candidate for one of the most common food allergies in the world and we are proud to be helping bring it to this critical phase I trial phase,” said Jean-Baptiste Agnus, Chief Business Officer at AGC Biologics. “This is a shining example of the ability and expertise of our global network to handle some of the most complex products and support our clients advancing through important clinical phases.”

A peanut allergy is one of the most common types of food allergies worldwide, and in the U.S., it is also a leading cause of severe and fatal food-induced anaphylactic reactions. Through this partnership, AGC Biologics will continue to work collaboratively with Allergy Therapeutics to develop the vaccine candidate that has the potential to provide relief for patients that have a critical need. 

“This is another key milestone for our VLP Peanut vaccine candidate, and we believe AGC Biologics is a great partner for us as we enter the next stage of bringing this promising immunotherapy to market,” said Manuel Llobet, Chief Executive Officer, Allergy Therapeutics. “We are excited to demonstrate the potential of this vaccine to provide long-term protection and a long-lasting protective immune response.”

AGC Biologics is producing this vaccine material at its state-of-the-art clinical and commercial manufacturing facility in Heidelberg, Germany. The site specializes in Microbial and Plasmid DNA (pDNA) offerings and is one of the company’s central facilities in Europe. The core team at the Heidelberg facility has several decades of experience delivering a wide range of programs, including work with BioNTech to supply COVID-19 vaccine materials.

For more information on AGC Biologics’ offerings visit www.agcbio.com/capabilities.

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

About VLP Peanut
VLP Peanut is being developed as a therapy for the treatment of peanut allergy. This novel immunogenic, protective, and non-reactogenic vaccine candidate is based on immunologically optimized Cucumber Mosaic Virus-derived VLPs (CuMVTT) with the major peanut allergen (Arachis hypogaea) (Ara h2) displayed on its surface. Patents behind the technology to treat peanut allergy with VLP Peanut have been granted in multiple territories.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Exterro Hires Rick Valentine as New Chief Customer Officer28.3.2024 14:00:00 CET | Press release

Seasoned executive will focus on ensuring Exterro customers maximize the value of their investment PORTLAND, Ore., March 28, 2024 (GLOBE NEWSWIRE) -- Exterro, the leading provider of data risk management software solutions, today announced the appointment of Rick Valentine, an expert in delivering world-class customer experiences at global organizations, as its new chief customer officer. The appointment reflects Exterro’s long-term commitment to delivering an outstanding experience and return on investment to all customers using its data risk management platform. Valentine will report directly to Exterro CEO Bobby Balachandran. Valentine brings more than three decades of leadership experience to the CCO position, most recently as chief customer officer at data management company Quantum. His prior executive experience encompasses both large public enterprises and high-growth startups in the high-tech space, including Silver Peak Systems/HPE, Veritas/Symantec, and Intuit. Valentine bri

Now Open for Nominations: The First Edition of the Stevie® Awards for Technology Excellence28.3.2024 14:00:00 CET | Press release

The newest edition of the world’s premier business awards will celebrate technology-related achievements worldwide FAIRFAX, Va., March 28, 2024 (GLOBE NEWSWIRE) -- The Stevie® Awards, organizers of the world’s premier business awards, have opened a ninth international competition: the Stevie® Awards for Technology Excellence. This new Stevie Awards program celebrates the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors. Individuals and organizations worldwide are eligible to enter – public and private, for-profit and non-profit, large and small. The program will recognize the world’s best technology professionals, organizations, achievements, products, and services since the beginning of 2022. The early-bird entry deadline, with reduced entry fees, is May 2. The entry deadline is May 30, but late entries will be accepted through June 28 with payment of a late fee. Entry details are available at www.StevieAw

HONKARAKENNE OYJ’S BOARD OF DIRECTORS DECIDED ON A SHARE-BASED INCENTIVE PROGRAM28.3.2024 14:00:00 CET | Press release

HONKARAKENNE OYJ Stock Exchange Release 28 March 2024 at 15:00 p.m. HONKARAKENNE OYJ’S BOARD OF DIRECTORS DECIDED ON A SHARE-BASED INCENTIVE PROGRAM As of 28.3.2024 The Board of Directors of Honkarakenne Oyj has decided on a share-based incentive program for 2024-2026. The purpose of the program is to engage key employees in the company’s objectives and create incentives for shareholder value growth. The performance share plan 2024-2026 consists of a 3-year performance period. Possible rewards will be paid in 2027, if the set performance targets are met. The performance metric applied to the performance period is company turnover and operating result %. The plan will involve a maximum of 9 individuals and the plan rewards will be equivalent to a maximum of 105,000 shares. HONKARAKENNE OYJ Board of Directors Additional information: CEO Marko Saarelainen, tel. +358 40 542 0254, marko.saarelainen@honka.com DISTRIBUTION Nasdaq Helsinki Ltd Key media Financial Supervisory Authority www.honk

Suominen extends the maturity of its revolving credit facility by one year28.3.2024 14:00:00 CET | Press release

Suominen Corporation’s press release on March 28, 2024 at 3:00p.m. (EET) Suominen signed in July 2020 a syndicated revolving credit facility agreement of EUR 100 million with maturity of three years with initially two one-year extension options, which both have been used. Suominen has now agreed on extending the maturity of the facility with additional year to July 2026. SUOMINEN CORPORATION For more information: Janne Silonsaari, CFO, tel. +358 50 409 9264 Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2023 were EUR 450.9 million and we have nearly 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 202328.3.2024 13:30:00 CET | Pressemelding

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 2023 Tractions årsredovisning och årsberättelse för 2023 är nu offentliggjorda och finns tillgängliga på bolagets webbplats, www.traction.se Den tryckta versionen av årsberättelsen kan beställas genom e-post till post@traction.se. AB Traction Petter Stillström Verkställande direktör Tel: 08-506 289 00 DENNA INFORMATION ÄR SÅDAN INFORMATION SOM AB TRACTION ÄR SKYLDIGT ATT OFFENTLIGGÖRA ENLIGT LAGEN OM VÄRDEPAPPERSMARKNADEN. INFORMATIONEN LÄMNADES FÖR OFFENTLIGGÖRANDE DEN 28 MARS 2024, KL. 13.30 CET. Bilagor Traction Årsredovisning 2023traction-2023-12-31-svTraction Årsberättelse 2023

HiddenA line styled icon from Orion Icon Library.Eye